Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- MSD, Bayer Yakuhin to Comarket Zetia-Statin Combo Drugs
July 10, 2017
- Maruho Takes Over Marketing Authorization for Astellas’ Protopic Ointment
July 10, 2017
- RaQualia Aiming for Market Capitalization of 100 Billion Yen by Around 2020: CEO
July 10, 2017
- Konica Minolta Buying US Diagnostics Firm to Fully Enter Precision Medicine Biz
July 7, 2017
- Nippon Chemiphar Sounds Positive about Authorized Generic Biz
July 7, 2017
- Shire Japan Files Hereditary Angioedema Drug Icatibant
July 7, 2017
- AZ Eyes Japan Durvalumab Launch in NSCLC Maintenance Therapy, Looks to Come from Behind in I/O Race
July 7, 2017
- Meiji Seika Pharma Launches 1st AG with Meiact Generic
July 6, 2017
- Finishing Line Already in Sight for Govt’s Biosimilar Doubling Goal? Uncertainty Remains with Approval Delays, Discontinuations
July 6, 2017
- Daiichi Sankyo Drops Enbrel Biosimilar Development in Japan
July 6, 2017
- Delving into Securities Filings - Part 2: Mid-Sized Firms’ Average Pay Dips, 24 Execs Earn Over 100 Million Yen
July 5, 2017
- Sumitomo Dainippon’s US Subsidiary Renamed
July 5, 2017
- J-TEC Wins Cultured Epidermis Order from Nagoya City Univ. Hospital
July 4, 2017
- French Biotech Oncodesign Set to Expand POC Services
July 4, 2017
- Aspen Japan to Take Over 4 Brands from Kyowa Kirin
July 4, 2017
- Sanofi Succeeds 4 Boehringer Brands in Japan under Global Asset Swap
July 4, 2017
- Signifor Filed for Cushing’s Disease in Japan: Novartis
July 4, 2017
- FDA Accepts NDA Resubmission for Sunovion’s COPD Med
July 4, 2017
- Evaluate Forecasts CAGR of 3.3% for Japan Market
July 4, 2017
- Delving into Securities Filings - Part 1: 27 Drug Makers’ Workforce Down 0.5% as Major Firms Continue to Shed Jobs
July 4, 2017
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…